Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Drugs Block Synthesis of Metabolites by Nutrient-Challenged Bacteria

By LabMedica International staff writers
Posted on 24 Oct 2013
Researchers have developed a new generation of antibiotics that kill bacteria by preventing them from making critical metabolites such as vitamins and amino acids.

Characterizing new drugs has been hindered by the difficulties inherent in identifying the mechanism of action (MOA) of biologically active molecules. More...
To attack this problem, investigators at McMaster University (Hamilton, ON, Canada) developed a metabolite suppression approach to explore the MOA of antibacterial compounds under conditions of nutrient restriction.

They assembled an array of metabolites that could be screened for suppressors of inhibitory molecules. Further, they identified inhibitors of Escherichia coli growth under nutrient limitation and charted their interactions with the metabolite array. This strategy led to the discovery and characterization of three new antibacterial compounds, MAC168425 (3-(dimethylamino)-1-(4-methoxyphenyl)propan-1-one), MAC173979 (3,3-dichloro-1-(3-nitrophenyl)prop-2-en-1-one), and MAC13772 (2-(2-nitrophenylthio)acetohydrazide). MAC168425 was found to interfere with glycine metabolism, MAC173979 was a time-dependent inhibitor of p-aminobenzoic acid biosynthesis, and MAC13772 inhibited biotin biosynthesis. These findings were published in the October 13, 2013, online edition of the journal Nature Chemical Biology.

"We have developed technology to find new antibiotics using laboratory conditions that mimic those of infection in the human body," said senior author Dr. Eric Brown, professor of biochemistry and biomedical sciences at McMaster University.

"We are taking fresh aim at bacterial vitamin and amino acid production and finding completely novel antibacterial compounds," said Dr. Brown. "We threw away chemicals that blocked growth in conventional nutrient-rich conditions and focused instead on those that were only active in nutrient-poor conditions. The approach belies conventional thinking in antibiotic research and development, where researchers typically look for chemicals that block growth in the laboratory under nutrient-rich conditions, where vitamins and amino acids are plentiful, but in the human body these substances are in surprisingly short supply and the bacteria are forced to make these and other building blocks from scratch."

Related Links:

McMaster University



New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.